Reconciliação medicamentosa em pacientes com diagnóstico de mieloma múltiplo em tratamento com transplante de medula óssea: revisão sistemática de literatura

Abstract

Introduction: Multiple myeloma (MM) is a hematological cancer that affects plasma cells that multiply uncontrollably in the bone marrow. The primary objective of MM treatment is to increase survival time and quality of life by reducing the manifestations of the disease and its signs and symptoms, while also seeking to minimize the adverse effects of treatment. Currently, multimodal therapies consist of stem cell transplantation, proteasome inhibitors, immunomodulators and monoclonal antibodies. Objective: To describe medication reconciliation in the setting of multiple myeloma in patients undergoing bone marrow transplantation available in the literature. Methods: To identify relevant articles, a search was conducted on three information platforms: MEDLINE/PubMed, Cochrane and Virtual Health Library (VHL), using the PICO approach, where the MeSH/DeCs terms and Boolean operators were adjusted according to necessary. Results: 1870 articles were found, of which, after using the PRISMA methodology, 16 articles remained for systematic review that addressed new therapies in multiple myeloma, increased overall survival and the absence of medication reconciliation in bone marrow transplant patients. Increased survival not only provides longer life, but offers the opportunity to explore new treatment options, elucidating their mechanisms of action and possible medication combinations. Conclusion: However, it was found in the studies that overall survival increased in patients undergoing bone marrow transplantation, however, medication reconciliation does not occur in these patients, with the need for further studies into actions to carry out this practice.